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Mutations that activate the LRRK2 (leucine-rich repeat protein kinase 2) protein kinase
predispose to Parkinson’s disease, suggesting that LRRK2 inhibitors might have thera-
peutic beneﬁt. Recent work has revealed that LRRK2 phosphorylates a subgroup of 14
Rab proteins, including Rab10, at a speciﬁc residue located at the centre of its effector-
binding switch-II motif. In the present study, we analyse the selectivity and sensitivity of
polyclonal and monoclonal phospho-speciﬁc antibodies raised against nine different
LRRK2-phosphorylated Rab proteins (Rab3A/3B/3C/3D, Rab5A/5B/5C, Rab8A/8B,
Rab10, Rab12, Rab29[T71], Rab29[S72], Rab35 and Rab43). We identify rabbit monoclo-
nal phospho-speciﬁc antibodies (MJFF-pRAB10) that are exquisitely selective for LRRK2-
phosphorylated Rab10, detecting endogenous phosphorylated Rab10 in all analysed cell
lines and tissues, including human brain cingulate cortex. We demonstrate that the
MJFF-pRAB10 antibodies can be deployed to assess enhanced Rab10 phosphorylation
resulting from pathogenic (R1441C/G or G2019S) LRRK2 knock-in mutations as well as
the impact of LRRK2 inhibitor treatment. We also identify rabbit monoclonal antibodies
displaying broad speciﬁcity (MJFF-pRAB8) that can be utilised to assess LRRK2-con-
trolled phosphorylation of a range of endogenous Rab proteins, including Rab8A, Rab10
and Rab35. The antibodies described in the present study will help with the assessment
of LRRK2 activity and examination of which Rab proteins are phosphorylated in vivo.
These antibodies could also be used to assess the impact of LRRK2 inhibitors in future
clinical trials.
Introduction
Commonly occurring autosomal-dominant missense mutations within the LRRK2 (leucine-rich repeat
protein kinase 2) protein are linked to Parkinson’s disease [1,2]. Mutations in LRRK2 are observed in
∼1% of sporadic and ∼5% of familial Parkinson’s patients [3]. LRRK2 is a large protein containing
numerous domains including a ROC/COR-type GTPase and a serine/threonine protein kinase [4].
The most frequent pathogenic mutation (G2019S) is located within the kinase domain and directly
enhances kinase activity, suggesting that LRRK2 inhibitors might offer therapeutic beneﬁt for prevent-
ing and treating Parkinson’s disease [5–8]. Because of this, several pharmaceutical companies have
generated highly selective, potent and brain-penetrable LRRK2 inhibitors that are in the late stage of
preclinical development [9].
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Recent studies have identiﬁed key physiological substrates of LRRK2 as members of the Rab GTPase family
including Rab8A and Rab10 [10–13]. LRRK2 phosphorylates Rab proteins at an evolutionarily conserved Ser/
Thr site lying within the effector-binding, switch-II motif (e.g. Thr72 for Rab8A and Thr73 for Rab10) [10].
All clear-cut LRRK2 pathogenic mutations tested, including the G2019S mutant, as well as the R1441G/C and
Y1699C mutations located within the ROC/COR GTPase domain, markedly elevate Rab10 phosphorylation in
cell lines (HEK293 and mouse embryonic ﬁbroblasts) as well as mouse tissues (the brain, spleen, lung and
kidney) [10,11].
Recent work has revealed that 14 Rab proteins (Rab3A/B/C/D, Rab5A/B/C, Rab8A/B, Rab10, Rab12, Rab29,
Rab35 and Rab43) are phosphorylated by LRRK2 in a HEK293 cell overexpression system [12]. Moreover, at
least 23 other Rab proteins that are not LRRK2 substrates are also phosphorylated at the equivalent switch-II
phosphorylation site [12]. These include Rab1, which is phosphorylated at the switch-II motif site by TAK1
kinase (Thr75) [14], as well as Rab7 (Ser72) that is phosphorylated by an unknown kinase during endosome
maturation [15,16]. Thus, at least 37 of the 70 Rab proteins are phosphorylated within the effector-binding
switch-II motif, and this is likely to represent a major mechanism by which Rab proteins are controlled.
Endogenous Rab protein phosphorylation has until now been largely assessed by mass spectrometry
[10,12,13] or by the ability of the Phos-tag reagent to retard the electrophoretic mobility of
LRRK2-phosphorylated Rab proteins [11]. Polyclonal antibodies to various LRRK2 Rab protein phosphoryl-
ation sites have also been raised [10,13], but the selectivity of these antibodies towards the various Rab proteins
phosphorylated by LRRK2 has not been rigorously assessed. As the residues encompassing the switch-II phos-
phorylation sites on the Rab proteins are highly similar (Figure 1), it is likely that polyclonal antibodies raised
against these sites will cross-react with multiple phosphorylated Rab proteins, thus complicating analysis.
In this study, we describe our efforts to develop polyclonal and monoclonal antibodies towards
LRRK2-phosphorylated Rab proteins and our approach to rigorously assess antibody speciﬁcity and potency.
This effort resulted in the development of a series of sensitive and highly selective rabbit monoclonal
phospho-antibodies (MJFF-pRAB10) that detect endogenous LRRK2-phosphorylated Rab10, in all cell lines
and tissues we have analysed, including human brain. We also identify rabbit monoclonal antibodies
(MJFF-pRAB8) that efﬁciently immunoprecipitate a subgroup of endogenous LRRK2-phosphorylated Rab pro-
teins (Rab8A, Rab10 and Rab35) that can therefore be deployed to assess LRRK2-mediated phosphorylation of
multiple endogenous Rab proteins. The antibodies described in the present study will be valuable tools to
assess the impact that inhibitors and pathogenic mutations have on LRRK2 activity in vivo.
Figure 1. Sequence alignment encompassing the phosphorylation sites of the 14 Rab proteins phosphorylated by
LRRK2.
Phosphorylation sites marked in red. Sequence shown is human, but is identical in most other mammals including mouse.
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Materials and methods
Material
MLi-2 inhibitor was synthesised by Natalia Shpiro (University of Dundee) as described recently [17,18]. All
peptide antigens were synthesised by ‘peptides and elephants’ (http://www.peptides.de/) and HPLC-puriﬁed
and stored in aliquots in sealed glass ampules in argon to avoid oxidation. For each phospho-peptide antigen,
we also ordered a dephosphorylated version that was used for negative afﬁnity puriﬁcation or for inclusion in
immunoblotting conditions (sheep polyclonal antibodies only).
Sheep polyclonal antibodies
Table 1 summarises the sheep phospho-speciﬁc and total Rab polyclonal antibodies generated for the present
study. It includes details of the antigens utilised and sheep numbers for each antibody programme. An add-
itional N-terminal Cys residue was added to each peptide antigen to conjugate the peptide to both keyhole
limpet haemocyanin (KLH) and bovine serum albumin [19]. Sheep were immunised with each antigen followed
by up to 12 further injections 28 days apart, with bleeds performed 7 days after each injection. Antibodies were
afﬁnity-puriﬁed from serum using the same phospho-peptides or Rab protein antigen that they were raised
against [19]. For total antibodies, a recombinant Rab protein with a different epitope tag than that used for
immunisation was employed for afﬁnity puriﬁcations (Table 1). All sheep afﬁnity-puriﬁed antibodies were used
for immunoblotting at ﬁnal concentrations of 1 mg/ml (in 5% non-fat milk in TBS-T), and for
phospho-antibodies, immunoblotting was conducted in the presence of 10 mg/ml of non-phosphorylated
peptide antigen in order to sequester any non-phospho-speciﬁc antibody. All bleeds of each antibody were eval-
uated and data are summarised in Supplementary Figure S1. All sheep polyclonal antibodies generated for the
present study can be requested via our reagents website (https://mrcppureagents.dundee.ac.uk/).
Rabbit polyclonal and monoclonal antibodies
Rabbit immunisation and rabbit antibody generation were performed by Abcam, Inc. (Burlingame, CA). Eight
New Zealand White rabbits were immunised with target peptides described in Table 2 for each antibody using
a standard protocol of ﬁve injections and two bleedings for each rabbit. Three subcutaneous injections were
performed using the KLH immunogens, followed by two subcutaneous injections using the ovalbumin immu-
nogens. At the time of each injection, an immunogen aliquot was thawed and combined with Complete
Freund’s Adjuvant (initial immunisation) or with incomplete Freund’s Adjuvant (for the subsequent injec-
tions). Serum bleeds of 25 ml were obtained after the fourth and ﬁfth immunisations (50 ml total). Antibodies
were afﬁnity-puriﬁed at this stage and evaluated in parallel with serum. One rabbit producing the best antibody
was chosen for monoclonal antibody generation and was intravenously boosted with immunogen 4 days before
Table 1 Antigens employed for sheep polyclonal phospho-specific and total Rab antibodies
Phosphorylated serine/threonine marked with S*/T*.
Antibody Sheep number Antigen
Rab3 pThr86 SA082 CAGQERYRT*ITTAYYR
Rab5 pSer84 S942D CAGQERYHS*LAPMYYR
Rab7L1 (Rab29) pThr71 S877D CIAGQERFT*SMTRLYYR
Rab7L1 (Rab29) pSer72 SA136 CDIAGQERFTS*MTRLYYRSS
Rab8 pThr72 S874D CAGQERFRT*ITTAYYR
Rab10 pThr73 S873D CAGQERFHT*ITTSYYR
Rab12 pSer106 S876D CAGQERFNS*ITSAYYR
Rab35 pThr72 SA083 CAGQERFRT*ITSTYYR
Rab43 pThr82 SA334 CAGQERFRT*ITQSYYR
Rab12 total SA227 Rab12 (no epitope tag) (affinity-purified with 6HIS-SUMO-Rab12)
Rab35 total SA314 GST-Rab35 (affinity-purified with MBP-Rab35)
Rab43 total SA135 GST-Rab43 (affinity-purified with HIS-SUMO-Rab43)
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splenectomy. Hybridoma fusion was performed according to the established protocol with minor modiﬁcations
[20]. Brieﬂy, splenocytes were harvested from the immunised rabbit and fused with rabbit plasmacytoma cells
240E-W2 [21] using PEG4000 (Sigma Chemical, St. Louis, MO) and selected by HAT (hypoxanthine, aminop-
terin and thymidine). At the end of the selection, hybridoma clones growing in the original 96-well plates were
transferred to 24-well plates with a medium change. Hybridoma supernatants were collected and screened for
antigen binding by enzyme-linked immunosorbent assay (ELISA) and western blot. Hybridomas that were spe-
ciﬁc in both assays were subcloned, expanded and frozen for future use. All rabbit polyclonal and monoclonal
antibodies were diluted in 5% BSA (bovine serum albumin) in TBS-T. The MJFF-pRab8 and MJFF-pRab10
rabbit monoclonal antibodies will be available commercially from Abcam (www.abcam.com) in 2018. Table 3
lists the MJFF antibodies analysed in the present study with future Abcam catalogue number.
Commercial antibodies
Anti-α-tubulin (#5174), anti-HA (#3724), anti-Rab8A (#6975), anti-Rab10 (#8127) and anti-phospho-p44/42
MAPK (Erk1/2) (#9101) were from Cell Signaling Technologies. Anti-ERK1 (C16) was from Santa Cruz
(sc-93). Mouse anti-LRRK2 antibody was from Antibodies, Inc. (#75-253). Rabbit monoclonal antibodies for
Table 2 Antigens employed for rabbit polyclonal and monoclonal phospho-specific Rab antibodies
Phosphorylated serine/threonine marked with S*/T*.
Antibody
Abcam
project
number Antigen
Rabbit
numbers
Name of final
monoclonal
antibodies
Rab8
pThr72
MJF-20 C-Ahx-AGQERFRT*ITTAYYR-amide E8262-E8269 MJFF-pRab8
Ac-AGQERFRT*ITTAYYR-Ahx-C
Rab10
pThr73
MJF-21 C-Ahx-AGQERFHT*ITTSYYR-amide E8254-E8261 MJFF-pRab10
Ac-AGQERFHT*ITTSYYR-Ahx-C
Table 3 MJFF-pRab8 and MJFF-pRab10
monoclonal phospho-specific Rab antibodies
MJFF clone name Abcam catalogue number
MJFF-pRab8clone-1 MJF-20-25-2
MJFF-pRab8clone-2 MJF-20-55-4
MJFF-pRab8clone-3 MJF-20-19-6
MJFF-pRab8clone-4 MJF-20-19-3
MJFF-pRab8clone-5 MJF-20-25-5
MJFF-pRab8clone-6 MJF-20-38-1
MJFF-pRab8clone-7 MJF-20-55-3
MJFF-pRab8clone-8 MJF-20-58-2
MJFF-pRab8clone-9 MJF-20-58-6
MJFF-pRab10clone-1 MJF-21-108-10
MJFF-pRab10clone-2 MJF-21-83-4
MJFF-pRab10clone-3 MJF-21-136-1
MJFF-pRab10clone-4 MJF-21-108-1
MJFF-pRab10clone-5 MJF-21-22-5
MJFF-pRab10clone-6 MJF-21-233-3
MJFF-pRab10clone-7 MJF-21-250-7
MJFF-pRab10clone-8 MJF-21-279-2
MJFF-pRab10clone-9 MJF-21-279-6
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total LRRK2 (UDD3) and pS935-LRRK2 (UDD2) were puriﬁed at the University of Dundee as described previ-
ously [22]. All commercially available antibodies were diluted in 5% BSA in TBS-T. The MJFF-total Rab10
antibody [23] generated by nanoTools (www.nanotools.de) will be commercialised by the Michael J Fox
Foundation in early 2018.
Plasmids
Constructs for overexpression of LRRK2 and Rab employed in the present study were generated at the
University of Dundee. Constructs utilised were HA-Rab3A (DU51539), HA-Rab3B (DU55007), HA-Rab3C
(DU55048), HA-Rab3D (DU26388), HA-Rab5A (DU26389), HA-Rab5B (DU26106), HA-Rab5C (DU47956),
HA-Rab8A (DU35414), HA-Rab8B (DU39856), HA-Rab10 (DU44250), HA-Rab12 (DU48963), HA-Rab29
(DU50222), HA-Rab35 (DU26478), HA-Rab43 (DU26392), ﬂag-LRRK2-WT (DU6841) and ﬂag-LRRK2-
Y1699C (DU13165). Data sheets for each construct can be viewed and constructs requested on our reagents
website (https://mrcppureagents.dundee.ac.uk/).
Mice
All animal studies were ethically reviewed and carried out in accordance with Animals (Scientiﬁc Procedures)
Act 1986 and regulations set by the University of Dundee and the U.K. Home Ofﬁce were strictly adhered to.
Animal studies and breeding were approved by the University of Dundee ethical committee and performed
under a U.K. Home Ofﬁce project licence. Mice were multiply housed at an ambient temperature (20–24°C)
and humidity (45–55%) maintained on a 12 h light/12 h dark cycle, with free access to food (SDS RM No. 3
autoclavable) and water. The LRRK2[R1441G] knock-in mice were described previously [24]. The LRRK2
[R1441C] knock-in mice were obtained from Jackson Laboratory ( JAX stock #009347 [25]) and maintained on
a C57BL/6J background. Mice were maintained under speciﬁc pathogen-free conditions at the University of
Dundee (U.K.). Genotyping of mice was performed by PCR using genomic DNA isolated from ear biopsies.
Primer 1 (50-CTGCAGGCTACTAGATGGTCAAGGT-30) and Primer 2 (50-CTAGATAGGACCGAGTGTCGC
AGAG-30) were used to detect the wild-type and knock-in alleles. The PCR programme consisted of 5 min at
95°C, then 35 cycles of 30 s at 95°C, 30 s at 60°C and 30 s at 72°C, and 5 min at 72°C. DNA sequencing was
used to conﬁrm the knock-in mutation and performed by DNA Sequencing & Services (MRC-PPU; http://
www.dnaseq.co.uk) using Applied Biosystems Big-Dye version 3.1 chemistry on an Applied Biosystems model
3730 automated capillary DNA sequencer.
For experiments shown in Figures 5 and 6, age-matched wild-type and LRRK2 knock-in mice (3–6 months
of age) were injected subcutaneously either with vehicle [40% (w/v) (2-hydroxypropyl)-β-cyclodextrin (Sigma–
Aldrich)] or MLi-2 dissolved in vehicle at 3 mg/kg dose and killed by cervical dislocation 60 min after treat-
ment. Tissues were rapidly isolated and snap-frozen in liquid nitrogen. MLi-2 (10 mg/kg) was used for R1441C
mice.
Cell culture, transfection, treatments and lysis
HEK293 and A549 cells were cultured in Dulbecco’s modiﬁed Eagle medium (Glutamax and Gibco) supple-
mented with 10% foetal calf serum, 100 U/ml penicillin and 100 mg/ml streptomycin. For culturing of mouse
embryonic ﬁbroblasts (MEFs), the medium was additionally supplemented with non-essential amino acids (Life
Technologies) and 1 mM sodium pyruvate (Life Technologies). All cells were regularly tested for mycoplasma
contamination. Transient transfections of HEK293 cells were performed 24–48 h prior to cell lysis using poly-
ethylenimine PEIMax (Polysciences). For PEI transfections on a 10 cm diameter dish of ∼70% conﬂuent
HEK293 cells, 1 ml of Dulbecco’s modiﬁed Eagle medium was mixed with 6.6 mg of plasmid DNA and 20 ml
of polyethylenimine (0.1% w/v), and incubated at room temperature for 30 min. For co-transfections of LRRK2
and Rab proteins, we typically transfected using 5.3 mg of LRRK2 construct and 1.3 mg of Rab construct (i.e.
ratio of 4:1). This DNA–polyethylenimine mixture was added dropwise to the cells. Prior to cell lysis, cells were
washed with TBS (20 mM Tris–HCl, pH 7.5, and 150 mM NaCl) on ice and lysed in an ice-cold lysis buffer
containing 50 mM Tris–HCl, pH 7.5, 1% (v/v) Triton X-100, 1 mM EGTA, 1 mM sodium orthovanadate,
50 mM NaF, 0.1% (v/v) 2-mercaptoethanol, 10 mM 2-glycerophosphate, 5 mM sodium pyrophosphate, 0.1 mg/
ml microcystin-LR (Enzo Life Sciences), 270 mM sucrose and complete EDTA-free protease inhibitor cocktail
(Sigma–Aldrich Cat # 11836170001). Lysates were centrifuged at 20 800 g for 15 min at 4°C and supernatants
were used for the Bradford assay (Thermo Scientiﬁc) and immunoblot analysis.
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Generation of mouse embryonic ﬁbroblasts
Littermate-matched wild-type and homozygous mutant mouse embryonic ﬁbroblasts (MEFs) were isolated
from mouse embryos at day E12.5 as described previously [26]. The LRRK2[R1441C] knock-in mice were
obtained from The Jackson Laboratory. The LRRK2[R1441G] knock-in MEFs were described recently [11].
LRRK2[G2019S] knock-in MEFs were generated from knock-in mice originally provided by Eli Lilly that are
now distributed through Taconic (line 13940). LRRK2[G2019S] MEFs were generated from the Eli Lilly mice as
described recently [10]. Littermate-matched wild-type and homozygous knock-out MEFs were isolated from
LRRK2 knock-out mice [22] as described previously [27]. All knock-in and knock-out cell lines were veriﬁed
by allelic sequencing.
Generation of CRISPR–Cas9 knock-out cell lines
The A549 Rab8A knock-out and Rab10 knock-out cell lines have been described previously [11, 12].
Mouse tissue lysate preparation
Frozen mouse tissues were weighed and added to a 10-fold volume excess of ice-cold lysis buffer containing
50 mM Tris–HCl, pH 7.5, 1% (v/v) Triton X-100, 1 mM EGTA, 1 mM sodium orthovanadate, 50 mM NaF,
0.1% (v/v) 2-mercaptoethanol, 10 mM 2-glycerophosphate, 5 mM sodium pyrophosphate, 0.1 mg/ml
microcystin-LR (Enzo Life Sciences), 270 mM sucrose and complete EDTA-free protease inhibitor cocktail
(Sigma–Aldrich Cat # 11836170001), and homogenised using a POLYTRON homogenizer (KINEMATICA) on
ice (5 s homogenisation, 10 s interval and 5 s homogenisation). Lysates were centrifuged at 20 800 g for 30 min
at 4°C and supernatants were used for Bradford assay and immunoblot analysis. Protein lysate (10–40 mg) was
obtained from each tissue sample.
Human brain lysate preparation
Human brain samples were provided by the Queen Square Brain Bank for Neurological Disorders (UCL, London).
Frozen human cingulate cortex samples were weighed and added to a 10-fold volume excess of ice-cold lysis buffer
containing 50 mM Tris–HCl pH 7.5, 1% (v/v) Triton X-100, 1 mM EGTA, 1 mM sodium orthovanadate, 50 mM
sodium ﬂuoride, 10 mM β-glycerophosphate, 5 mM sodium pyrophosphate, 0.1 mg/ml Microcystin-LR (Enzo Life
Sciences), 270 mM sucrose and complete EDTA-free protease inhibitor cocktail ((Sigma–Aldrich Cat #
11836170001), and homogenised using POLYTRON homogenizer (KINEMATICA) on ice (5 s homogenisation,
10 s interval and 5 s homogenisation). Lysates were centrifuged at 20 800 g for 10 min at 4°C. Supernatants
were collected, quantiﬁed by the Bradford assay (Thermo Scientiﬁc) and subjected to immunoblot analysis.
Immunoblot analysis
Cell or tissue lysates were prepared in SDS–PAGE sample buffer [50 mM Tris–HCl, pH 6.8, 2% (w/v) SDS,
10% (v/v) glycerol, 0.02% (w/v) Bromophenol Blue and 1% (v/v) 2-mercaptoethanol] and heated at 95°C for
5 min. Electrophoresis was undertaken using the NuPAGE Bis–Tris 4–12% gradient gels (Life Technologies)
run at 150 V. Proteins were then transferred onto the nitrocellulose membrane (GE Healthcare, Amersham
Protran Supported 0.45 mm NC) at 90 V for 90 min. Membranes after transfer were blocked with 5% (w/v)
non-fat dry milk dissolved in TBS-T [20 mM Tris–HCl, pH 7.5, 150 mM NaCl and 0.1% (v/v) Tween 20] at
room temperature for 45 min. Membranes were then incubated with primary antibodies diluted in 5% BSA
(bovine serum albumin) in TBS-T (rabbit polyclonal and monoclonal antibodies) or in 5% non-fat milk in
TBS-T (sheep polyclonal antibodies) overnight at 4°C. After washing membranes in TBS-T, membranes were
incubated at room temperature for 1 h with either HRP-labelled secondary antibody (Thermo Fisher Scientiﬁc
#31480, #31460, #31430) diluted (1 : 2500) in 5% non-fat dry milk/TBS-T or with near-infrared ﬂuorescent
IRDye antibodies (LI-COR #925-68070, #925-32211) diluted (1 : 20 000) in TBS-T (without milk or BSA). The
membranes, after washing in TBS-T, were developed either using ECL [Amersham ECL Western Blotting
Detection Reagents (GE Healthcare)] or using the LI-COR Odyssey CLx Western Blot imaging system.
Phos-tag SDS–PAGE
Phos-tag SDS–PAGE was performed following the general protocol recently described [11], with modiﬁed con-
centration of the Phos-tag reagent used (100 mM Phos-tag acrylamide and 200 mM MnCl2). The membranes
were developed using ECL [Amersham ECL Western Blotting Detection Reagents (GE Healthcare)].
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Immunoprecipitation of Rab proteins
For the endogenous Rab immunoprecipitations from LRRK2[R1441C/G] and wild-type MEF ±MLi2, the cells
were treated with or without 100 nM MLi-2 for 90 min and lysed in an ice-cold lysis buffer containing 50 mM
Tris–HCl, pH 7.5, 1% (v/v) Triton X-100, 10% (v/v) glycerol, 1 mM sodium orthovanadate, 50 mM NaF,
10 mM 2-glycerophosphate, 5 mM sodium pyrophosphate, 0.1 mg/ml microcystin-LR (Enzo Life Sciences) and
complete EDTA-free protease inhibitor cocktail (Sigma–Aldrich Cat # 11836170001).
The rabbit polyclonal and monoclonal Rab8 phospho-Thr72 antibodies were covalently linked to Protein
A-agarose beads using dimethyl pimelimidate [19], at the ratio of 0.2 mg of antibody per 1 ml of beads for
monoclonal antibody or 1 mg of antibody per 1 ml of beads for polyclonal antibody. Immunoprecipitations
were conducted by incubating 50 ml of conjugated antibody resin, washed in lysis buffer, with 5 mg of MEF
extract. After 2 h at 4°C, the beads were then washed three times with phosphate-buffered saline and incubated
with 20 ml of 2× SDS–PAGE sample buffer for 2 min at room temperature. The suspension was then centri-
fuged through a 0.22 mm Spinex ﬁlter and the eluate heated to 95°C for 10 min and subjected to immunoblot
analysis with diverse Rab protein total antibodies.
For the immunoprecipitation of endogenous Rab12 from MEF lysates prepared as described above, sheep
polyclonal Rab12 (SA227) antibody was cross-linked to Protein-G-agarose beads at the ratio of 1 mg of anti-
body per 2 ml of beads using dimethyl pimelimidate [19]. Immunoprecipitations were conducted by incubating
50 ml of conjugated antibody resin washed in lysis buffer with 5 mg of MEF extract. After 2 h incubation at
4°C, the beads were washed three times with phosphate-buffered saline and incubated with 50 ml of 2× SDS–
PAGE sample buffer for 2 min at room temperature. The suspension was centrifuged through a 0.22 mm
Spinex ﬁlter, and the eluate was heated to 95°C for 10 min and subjected to immunoblot analysis with the Rab
phospho-Rab12 pS106 (S876D) antibody.
In vitro phosphorylation of Rab8A and Rab10 by LRRK2
Recombinant Rab8A and Rab10 were expressed and puriﬁed as described previously [10, 11]. Puriﬁed proteins
were phosphorylated using full-length LRRK2[G2019S] (Invitrogen) in a buffer containing 50 mM Tris–HCl,
pH 7.5, 0.1 mM EGTA, 10 mM MgCl2 and 1 mM ATP (50 ml total volume). A reaction where no LRRK2 was
added was also included as a negative control. The kinase reactions were carried out for 4 h at room tempera-
ture in Dispo-Biodialysers of 1 kDa molecular mass cut-off (Sigma–Aldrich) put in 0.5 l of the same buffer to
allow for the removal of kinase reaction product ADP and to maintain a high level of ATP, in order to maxi-
mise phosphorylation stoichiometry of Rab proteins. Kinase reactions were terminated by the addition of SDS–
PAGE sample containing 1% (by vol) 2-mercaptoethanol. Known amounts of Rab samples were subjected to
Phos-tag SDS–PAGE to assess the stoichiometry of Rab8A/Rab10 phosphorylation. This was used to calculate
the amount of phosphorylated Rab proteins and for the potency of MJFF-pRab8 (Figure 8C) and
MJFF-pRab10 (Figure 4C) to be assessed.
Results
Amino acid sequences encompassing Rab protein LRRK2 phosphorylation
sites
The sequences encompassing the phosphorylation site of the 14 Rab proteins that are phosphorylated by
LRRK2 are shown in Figure 1. Rab29 (also known as Rab7L1) is unique, as in addition to Ser72 that lies at the
equivalent position to other LRRK2 Rab protein phosphorylation sites, possesses an adjacent Thr71 residue
that is also phosphorylated by LRRK2 [12]. The sequences within Rab3 isoforms (Rab3A/Rab3B/Rab3C and
Rab3D), Rab5 isoforms (Rab5A/Rab5B and Rab5C) and Rab8 isoforms (Rab8A and Rab8B) are identical
(Figure 1). Therefore, there are 10 sets of unique sequences, differing by at least one residue that LRRK2
phospho-speciﬁc antibodies can be raised against, namely Rab3, Rab5, Rab8, Rab10, Rab12, Rab29 (Thr71),
Rab29 (Ser72), Rab29 (Thr71 + Ser72), Rab35 and Rab43 (Figure 1). It should be noted that only for Rab43,
the sequence motif that surrounds the LRRK2 phosphorylation site is identical with the sequence surrounding
Thr81 in Rab19 that is not thought to be an LRRK2 substrate [12]. Six of the Rab protein LRRK2 phosphoryl-
ation sites are on threonine residues (Rab3, Rab8, Rab10, Rab29[Thr71], Rab35 and Rab43) and three on
serine residues (Rab5, Rab12 and Rab29 [Ser72]), which could inﬂuence the selectivity of the phospho-speciﬁc
antibodies (Figure 1). The sequences surrounding each of the Rab protein LRRK2 phosphorylation sites are
© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 7
Biochemical Journal (2018) 475 1–22
https://doi.org/10.1042/BCJ20170802
identical in most mammals, including human and mouse, indicating that phospho-speciﬁc antibodies will have
utility in analysing LRRK2 signalling in a broad range of species.
Polyclonal phospho-speciﬁc Rab protein antibodies
We ﬁrst raised sheep polyclonal antibodies against phospho-peptides encompassing the LRRK2 phosphorylation
site of Rab3, Rab5, Rab8, Rab10, Rab12, Rab29-Thr71, Rab29-Ser72, Rab35 and Rab43 (Figure 2A). For each of
the sheep polyclonal antibodies, we immunised animals with a single phospho-peptide encompassing the LRRK2
phosphorylation site, conjugated via an N-terminal Cys residue to a mixture of KLH and bovine serum albumin
(Table 1). We also generated rabbit polyclonal antibodies against phospho-peptides encompassing the LRRK2
phosphorylation site on Rab8 and Rab10 (Figure 2B). For the rabbit antibodies, we adopted a novel strategy, in
which we immunised each animal with two antigen phospho-peptides (Table 2) encompassing the LRRK2 phos-
phorylation site that possesses a Cys-aminohexanoic acid moiety either on its N-terminus or C-terminus (Table 2).
We also blocked the remaining free terminal residue (acetyl group for N-terminus or amide for C-terminus)
(Table 2). These peptides were conjugated to KLH and ovalbumin via the terminal Cys residue prior to immunisa-
tion. This strategy was selected to maximise peptide exposure in both possible conjugation orientations and was
previously adopted to generate sensitive antibodies recognising PINK1 phosphorylated ubiquitin [28].
Polyclonal antibodies were evaluated after afﬁnity puriﬁcation on phospho-peptide antigen column, and for
rabbit antibodies, additional negative afﬁnity puriﬁcation on a non-phospho-peptide antigen column was per-
formed. To assess the selectivity of each antibody, we created a panel of different LRRK2-phosphorylated Rab
proteins in HEK293 cells, by overexpressing Rab proteins with pathogenic LRRK2[Y1699C]. Prior to lysis, cells
were treated with or without 150 nM MLi-2 LRRK2 inhibitor to enable phosphorylation dependence of each
Figure 2. Cross-reactivity of the polyclonal sheep and rabbit phospho-Rab protein antibodies.
HEK293 cell extracts overexpressing LRRK2[Y1699C] and the indicated HA-tagged Rab protein were treated ±150 nM MLi-2
for 90 min and then lysed. The cell lysates were immunoblotted with the indicated sheep (A) and rabbit (B) afﬁnity-puriﬁed
phospho-speciﬁc polyclonal antibodies (all at 1 mg/ml antibody — for only sheep polyclonal antibodies, we also included
10 mg/ml dephospho-peptide antigen). Ten micrograms of whole cell lysate were loaded per lane for the sheep polyclonal
antibodies (A) and 1 mg of cell lysate per lane for the rabbit polyclonal antibodies (B). Immunoblots developed with ECL.
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antibody to be established (Figure 2). This analysis revealed that all of the polyclonal sheep (Figure 2A) and
rabbit (Figure 2B) antibodies recognised the LRRK2-phosphorylated Rab protein to which they were raised
against in a MLi-2-sensitive manner. The polyclonal antibodies raised against Rab proteins with a Ser at the
LRRK2 phosphorylation site (Rab5 isoforms, Rab12 and Rab29), were more selective than antibodies raised
against Thr phosphorylation sites (Figure 2A). For example, Rab5 and Rab12 phospho-speciﬁc antibodies only
cross-reacted weakly or not at all with other LRRK2-phosphorylated Rab proteins (Figure 2A). The Rab29
[Ser72] phospho-antibody cross-reacted with Rab12 and Rab43, but not with other Rab proteins. In contrast,
polyclonal antibodies raised against Rab proteins possessing a Thr residue at the phosphorylation site (Rab3,
Rab8, Rab10, Rab35 and Rab 43) were not selective and cross-reacted with many other Rab proteins, especially
those phosphorylated on Thr residues (Figure 2A,B). The Rab35 and Rab43 phospho-antibodies did not cross-
react with LRRK2-phosphorylated Rab3 isoforms, but cross-reacted with all other Thr-phosphorylated Rab pro-
teins. The antibody raised against the Rab29[Thr71] site was also selective (Figure 2A), presumably because it
is unique being one residue removed from the other LRRK2 phosphorylation sites. The relative speciﬁcity of
each of the polyclonal antibodies did not vary signiﬁcantly between antibody bleeds (Supplementary
Figure S1). The rabbit polyclonal antibodies were estimated to be ∼10-fold more sensitive than the sheep anti-
bodies, based on the relative amounts of HEK 293 extract required to detect a strong signal (1 mg for rabbit
polyclonal antibody versus 10 mg of HEK293 cell extract for sheep polyclonal antibody) (Figure 2A,B). It is
possible that the different peptide immunisation strategies deployed account for the differences in afﬁnity of
these antibodies. Further work comparing both strategies in parallel would be required to ascertain this.
Analysis of endogenous LRRK2-phosphorylated Rab proteins with polyclonal
phospho-speciﬁc antibodies
The rabbit polyclonal Rab8 and Rab10 phospho-speciﬁc antibodies readily detected endogenous Rab protein
phosphorylation in MEFs that have previously been used to assess LRRK2-mediated phosphorylation of Rab pro-
teins [10,11] (Figure 3A). Phosphorylation was inhibited by the treatment with MLi-2 or knock-out of LRRK2,
conﬁrming that the antibodies are detecting a LRRK2-regulated Rab protein phosphorylation (Figure 3A).
Moreover, LRRK2[G2019S], LRRK2[R1441C] and LRRK2[R1441G] knock-in mutations all increased Rab protein
phosphorylation 2- to 4-fold, and this increase was detected by either of the rabbit polyclonal Rab8 or Rab10 anti-
bodies (Figure 3A,B). The sheep polyclonal phospho-speciﬁc antibodies were insufﬁciently sensitive to detect
endogenous Rab protein phosphorylation by direct immunoblot analysis of whole cell lysates. However, by immu-
noprecipitating endogenous Rab12 protein and then immunoblotting with phospho-Rab12 sheep polyclonal anti-
bodies, we readily observed phosphorylated Rab12 in MEFs (Figure 3C). Moreover, employing this strategy, a
3-fold increase in the phosphorylation of Rab12 was observed in the LRRK2[R1441G] knock-in MEFs compared
with wild-type MEFs that were suppressed by MLi-2 LRRK2 inhibitor treatment (Figure 3C).
Development and characterisation of exquisitely speciﬁc MJFF-pRab10 rabbit
monoclonal antibodies
In an attempt to raise selective phospho-speciﬁc Rab10 protein antibodies, we initiated a programme to gener-
ate rabbit monoclonal antibodies. We assessed the selectivity and potency of the top 9 hybridoma clones
termed MJFF-pRAB10clones-1 to -9. Strikingly, they were all highly selective and did not cross-react with other
Thr LRRK2-phosphorylated Rab proteins (Figure 4A). To establish the in vivo selectivity of these clones, we
utilised previously described wild-type, Rab8A knock-out [12] and Rab10 knock-out [11] A549 cells that
express LRRK2, albeit at signiﬁcantly lower levels than MEFs. All the MJFF-pRAB10 monoclonal antibodies
readily detected phosphorylated Rab10 in wild-type and Rab8A knock-out, but not in Rab10 knock-out A549,
cells conﬁrming the exquisite speciﬁcity of these antibodies (Figure 4B). Treatment with MLi-2 also ablated rec-
ognition of phosphorylated Rab10 in A549 cells with all of the MJFF-pRab10 antibodies (Figure 4B). To
analyse the potency of each MJFF-pRAB10 monoclonal antibody, we immunoblotted a serial dilution of quan-
tiﬁed amounts of LRRK2-phosphorylated Rab10 (Figure 4C). This revealed that the antibodies were exception-
ally potent, detecting as little as 10 pg of LRRK2-phosphorylated Rab10 (0.44 fmol). These antibodies were
much more potent than the commercial total Rab10 antibody we routinely employ that detects ∼300–1000 pg
of Rab10 protein (Figure 4C, lower panel).
The MJFF-pRAB10 also recognised phosphorylated Rab10 in LRRK2[R1441G] knock-in MEFs in a manner
that was suppressed by MLi-2 treatment (Figure 4D). The immunoblots were strikingly clean, with the
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Figure 3. Detection of endogenous LRRK2-mediated Rab protein phosphorylation with polyclonal antibodies.
(A) The indicated littermate wild-type and knock-in or knock-out MEF cells were treated ±100 nM MLi-2 for 90 min and lysed.
The cell lysates (10 mg) were immunoblotted with the indicated antibodies and the membranes developed using the Odyssey
CLx Western Blot imaging system (all at 1 mg/ml antibody). Similar results were obtained in two independent experiments. (B)
Quantitation of immunoblots was undertaken by analysing pRab8/tubulin (Bi) or pRab10/tubulin (Bii). (C) As in (A) except that
Rab12 was immunoprecipitated using sheep polyclonal total Rab12 antibody from 5 mg of each of the indicated cell extracts.
Ninety percent of the immunoprecipitates was immunoblotted with the phospho-Rab12 pSer106 antibody and 1%
immunoblotted with the total Rab12 antibody (all at 1 mg/ml antibody and for the phospho-Rab12 pSer106 antibody, 10 mg/ml
of dephospho-peptide was also included). Immunoblot (A) developed with LI-COR, and immunoblot (C) developed with ECL.
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phosphorylated Rab10 being the only major protein in the extract recognised by the MJFF-pRAB10 antibodies
(Figure 4D). We immunoblotted a panel of wild-type and LRRK2 mutant MEFs with MJFF-pRAB10clone-1,
which conﬁrmed that 2- to 3-fold increased phosphorylation of Rab10 was readily observed with pathogenic
LRRK2[G2019S], LRRK2[R1441G] and LRRK2[R1441C] knock-in mutations and signal lost with LRRK2
knock-out or MLi-2 treatment (Figure 4E).
We next immunoblotted mouse spleen (Figure 5A), lung (Figure 5B), kidney (Figure 5C) and brain
(Figure 5D) extracts derived from littermate wild-type and homozygous LRRK2[R1441G] mice with the
MJFF-pRAB10 antibodies. Phosphorylated Rab10 was readily detected in the spleen, lung and kidney extracts
and enhanced 2- to 3-fold in LRRK2[R1441G] knock-in tissues compared with wild-type tissues (Figure 5A–C).
We also injected mice with an intermediate dose of LRRK2 inhibitor (3 mg/kg MLi-2) that partially reduces
LRRK2 activity and Rab10 phosphorylation in vivo [11]. Consistent with this, we observed that 3 mg/kg MLi-2
partially suppressed phosphorylation of Rab10 in the lung, spleen and kidney (Figure 5A–C) in addition to the
well-studied LRRK2 Ser935 biomarker phosphorylation that is controlled by LRRK2 kinase activity [22,29]
(Figure 5E). As observed before, Ser935 is largely ablated by the R1441G knock-in mutation for reasons that
are not understood [11,30]. Immunoblotting 40 mg of whole brain extract from wild-type mice revealed only a
weak phospho-Rab10 band that was not reduced by MLi-2 treatment (Figure 5D). Only a weak Ser935 phos-
phorylation signal was observed in the wild-type brain which was suppressed by MLi-2 (Figure 5E). In the
Figure 4. Characterisation of the selectivity and potency of MJFF-pRab10 rabbit monoclonal antibodies.
(A) HEK293 cell extracts overexpressing LRRK2[Y1699C] and the indicated HA-tagged Rab protein were treated ±150 nM
MLi-2 for 90 min and then lysed. The cell lysates (0.1 mg) were immunoblotted with the indicated MJFF-pRab10 hybridoma
clones (all at 0.5 mg/ml antibody). (B) The indicated wild-type and knock-out A549 cells were treated ±100 nM MLi-2 for 90 min
and then lysed. The cell lysates (20 mg) were immunoblotted with the indicated MJFF-pRab10 hybridoma clones as well as
shown total antibodies (all at 0.5 mg/ml antibody). (C) The indicated amounts of recombinant LRRK2-phosphorylated Rab10
were subjected to immunoblotting with the speciﬁed MJFF-pRab10 hybridoma clones as well as the total RAB10 antibody
purchased from Cell Signaling Technology (CST) (all at 0.5 mg/ml antibody). (D) LRRK2[R1441G] MEFSs were treated ±100 nM
MLi-2 for 90 min and then lysed. The cell lysates (5 mg) were immunoblotted with the indicated MJFF-pRab10 hybridoma
clones (all at 0.5 mg/ml antibody). (E) The indicated littermate wild-type and knock-in or knock-out MEF cells were treated
±100 nM MLi-2 for 90 min and lysed. The cell lysates (5 mg) were immunoblotted with the indicated antibodies and the
membranes developed using the Odyssey CLx scan Western Blot imaging system (all at 1 mg/ml antibody). Quantitation of
immunoblots was undertaken by analysing pRab10/tubulin (Ei). Immunoblots were developed with LI-COR.
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Figure 5. Characterisation of MJFF-pRab10 rabbit monoclonal antibodies in wild-type and LRRK2[R1441G] knock-in
mouse tissue extracts. Part 1 of 2
Wild-type and LRRK2[R1441G] knock-in mice were administered with MLi-2 (3 mg/kg) by subcutaneous injection. After 60 min,
animals were killed and the spleen (A), lung (B), kidney (C) and brain (D) extracts were generated and immunoblotted with the
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brain extract derived from LRRK2[R1441G] knock-in animals, the signal of phosphorylated Rab10 was similar
to that observed in wild-type mice, but was partially reduced by MLi-2 treatment (Figure 5D).
With tissues, the immunoblots were not as clean as observed with ﬁbroblasts (Figure 4D), but phosphory-
lated Rab10 was still a major band especially in the spleen (Figure 5A) and lung (Figure 5B).
MJFF-pRAB10clones-1 and -2 were selected for recombinant antibody production as these were judged to be the
most potent and selective antibodies.
To ensure that the recombinant pRAB10clone-1 and pRAB10clone-2 antibodies worked as well as original
hybridoma antibodies, we immunoblotted the lung, spleen, kidney and brain tissues of LRRK2[R1441C]
knock-in mice treated ±10 mg/kg MLi-2 with recombinant antibody (Figure 6). This conﬁrmed that phos-
phorylated Rab10 was readily detected in order of strength in the lung (best), then the spleen, kidney and brain
(weakest) (Figure 6A,B). MJFF-pRAB10clone-1 is more potent than MJFF-pRAB10clone-2 and readily detects
phosphorylated Rab10 in all four tissues (Figure 6A,B). MJFF-pRAB10clone-2 has a lower background on immu-
noblot analysis and clearly detects phosphorylated Rab10 in the lung and spleen with signiﬁcantly less back-
ground than the MJFF-pRAB10clone-1 antibody (Figure 6A). However, MJFF-pRAB10clone-2 antibody is less
sensitive than MJFF-pRAB10clone-1 antibody at recognising phosphorylated Rab10 in the kidney and brain
(Figure 6A,B). Both antibodies worked equally well in detecting LRRK2-phosphorylated Rab10 in MEFs and
A549 cells (Figure 4). Owing to its lower background, MJFF-pRAB10clone-2 may be better than MJFF-
pRAB10clone-1 in many cell lines and in the lung and spleen. However, if the signal of phosphorylated Rab10 is
weak, as it is for the kidney and brain in wild-type mice, we would recommend using pRAB10clone-1 antibody.
Analysis of Rab10 phosphorylation in the human brain cingulate cortex samples
To determine whether MJFF-pRAB10 monoclonal antibodies detect phosphorylated Rab10 in human brain, we
obtained from the Queen Square Brain Bank (UCL), cingulate cortex samples from 23 controls and 28 idio-
pathic Parkinson’s patients. Protein lysate (2–10 mg) was obtained from each tissue sample. Twenty micro-
grams of brain extracts derived from each sample was immunoblotted with the monoclonal
MJFF-pRAB10clone-1 antibody, revealing that levels of phosphorylated Rab10 were very low or non-detectable
in the majority of samples (Figure 7A). However, phosphorylated Rab10 was elevated in a few samples, espe-
cially in one of the idiopathic Parkinson’s samples (donor 1, derived from a 91-year-old female patient with no
known mutations) (Figure 7A). The panel contained ﬁve other cingulate cortex samples from patients over 90
years of age which did not display elevated levels of phosphorylated Rab10 (Figure 7A). pERK1/2 antibody was
used to analyse the general stability of phosphorylation across the samples. We observed the variability of
ERK1/2 phosphorylation levels with high levels seen in ﬁve controls and six to seven idiopathic samples
(Figure 7A). There was no correlation between Rab10 phosphorylation and ERK1/2 phosphorylation. In con-
trast, the levels of total ERK1/ERK2 were very similar in most samples (Figure 7A). We also attempted to
analyse LRRK2 Ser935 phosphorylation and Akt Ser473 phosphorylation, but this was found to be undetectable
for all samples. We also analysed the cingulate cortex samples employing phos-tag immunoblotting analysis, in
which retardation of the phosphorylated Rab10 on a phos-tag polyacrylamide gel was monitored with a total
Rab10 antibody (Figure 7B). Using this approach, only the same sample from the 91-year-old female
Parkinson’s patient displayed signiﬁcant levels of phosphorylated Rab10 (Figure 7B).
The total levels of Rab10 and Rab8A were fairly constant between the cingulate cortex samples (Figure 7A).
LRRK2 levels were much lower and varied signiﬁcantly, and were not detectable in a few samples (Figure 7A).
It is possible that LRRK2 being a large protein is more susceptible to post-mortem/long-term storage degrad-
ation compared with Rab proteins. The sample from idiopathic Parkinson’s donor 1 that displayed highest
levels of phosphorylated Rab10 had an intermediate level of LRRK2 (Figure 7A). We also subjected two con-
trols and two idiopathic cingulate cortex samples (one with higher Rab10 phosphorylation and one with lower
Figure 5. Characterisation of MJFF-pRab10 rabbit monoclonal antibodies in wild-type and LRRK2[R1441G] knock-in
mouse tissue extracts. Part 2 of 2
indicated MJFF-pRab10 hybridoma clones (all at 0.5 mg/ml antibody). Thirty micrograms of the extract were immunoblotted for
the spleen, lung, kidney and 40 mg for brain. (E) The denoted extracts were immunoblotted with the indicated total and
phospho-Ser935 LRRK2 antibodies. The regions of the nitrocellulose membrane containing phosphorylated Rab10 are
highlighted in a red box, *NS, major non-speciﬁc bands. Immunoblots were developed with LI-COR.
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Figure 6. Characterisation of MJFF-pRab10clone-1 and MJFF-pRab10clone-2 rabbit monoclonal antibodies in LRRK2
[R1441C] knock-in mouse tissue extracts.
LRRK2[R1441C] knock-in mice were administered with MLi-2 (10 mg/kg) by subcutaneous injection. After 60 min, animals were
killed, and the lung, spleen, kidney and brain extracts were generated and immunoblotted with the indicated MJFF-pRab10
hybridoma clones (at 1 mg/ml antibody). Forty micrograms of the extract were immunoblotted for the spleen, lung, kidney and
brain (A). Quantitation of immunoblots was undertaken by analysing pRab10/GAPDH (B). The regions of the nitrocellulose
membrane containing phosphorylated Rab10 are highlighted in a red box. *NS, major non-speciﬁc bands. Immunoblots were
developed with LI-COR.
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Rab10 phosphorylation) to immunoblot analysis with the MJFF-pRAB10clones-1 to -3 monoclonal antibodies
(Figure 7C). The immunoblots with all antibodies were remarkably clean, displaying only one major protein
corresponding to phosphorylated Rab10 (Figure 7C).
Development and characterisation of pan-selective MJFF-pRab8 rabbit
monoclonal antibodies
We also raised rabbit monoclonal phospho-antibodies for LRRK2-phosphorylated Rab8 and assessed the select-
ivity and potency of the top 9 hybridoma clones termed MJFF-pRAB8clones-1 to -9 (Figure 8). In contrast to
Figure 7. Phosphorylation of Rab10 in control and idiopathic Parkinson’s disease patients’ cingulate cortex.
(A) Cingulate cortex samples derived from Control (Ctrl) and idiopathic Parkinson’s disease (IPD) donors were obtained from
the Queen Square Brain Bank (UCL). Extracts from each of these were generated and 20 mg subjected to immunoblot analysis
using the indicated antibodies. Donors marked with an asterisk are over 90 years of age. The sample marked with an arrow
(IPD donor 1) displays the highest levels of Rab10 phosphorylation. (B) As in (A) except that samples were subjected to
Phos-tag polyacrylamide gel electrophoresis prior to immunoblot analysis employing a total Rab10 antibody. Cell lysates
prepared from LRRK2[R1441C] knock-in MEFs were used as a positive control (+) for Rab10 phosphorylation and run in the
last lane. The open circles on the Phos-tag gel correspond to the position that the phosphorylated Rab protein migrates and
the closed circle the position that the dephosphorylated Rab protein migrates. (C) Control (donors 1 and 2) and IPD samples
(donors 1 and 2) were subjected to immunoblot analysis using the MJFF-pRab10clone-1–3 monoclonal antibodies. The arrow
indicates the band corresponding to the phospho-Rab10 signal. Immunoblots were developed with LI-COR.
© 2018 The Author(s). This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY). 15
Biochemical Journal (2018) 475 1–22
https://doi.org/10.1042/BCJ20170802
Rab10, none of the MJFF-pRAB8 monoclonal antibodies were selective for LRRK2-phosphorylated Rab8A and
clearly recognised other LRRK2-phosphorylated Rab proteins with similar potency to Rab8A (Figure 8A).
MJFF-pRAB8clone-2 was the most selective, but still recognised other LRRK2-phosphorylated Rab proteins. Two
MJFF-pRAB8 antibodies detected a phosphorylated Rab species in wild-type A549 cells that were ablated with
LRRK2 inhibitors (MJFF-pRAB8clones-1 and -5). However, these antibodies are cross-reacting with
LRRK2-phosphorylated Rab10, as signal was lost with the Rab10 knock-out, but not with the Rab8A knock-out
Figure 8. Characterisation of the selectivity and potency of MJFF-pRab8 rabbit monoclonal antibodies.
(A) HEK293 cell extracts overexpressing LRRK2[Y1699C] and the indicated HA-tagged Rab protein were treated ±150 nM
MLi-2 for 90 min and then lysed. The cell lysates (0.1 mg) were immunoblotted with the indicated MJFF-pRab8 hybridoma
clones (all at 0.5 mg/ml antibody). (B) The indicated wild-type and knock-out A549 cells were treated ±100 nM MLi-2 for 90 min
and then lysed. The cell lysates (20 mg) were immunoblotted with the speciﬁed MJFF-pRab8 hybridoma clones and the
denoted total antibodies (all at 0.5 mg/ml antibody). (C) The shown amounts of recombinant LRRK2-phosphorylated Rab8A
were subjected to immunoblotting with the indicated MJFF-pRab8 hybridoma clones as well as the total RAB8A antibody
purchased from Cell Signaling Technology (CST) (all at 0.5 mg/ml antibody). Immunoblots were developed with LI-COR.
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(Figure 8B). We also immunoblotted a serial dilution of LRRK2-phosphorylated Rab8A with the selected
MJFF-pRAB8 antibodies, revealing that most of the Rab8 monoclonal antibody clones detected ∼30 pg of
LRRK2-phosphorylated Rab8 (1.27 fmol) (Figure 8C). The MJFF-pRAB8 antibodies are therefore moderately
less potent than the MJFF-pRAB10 antibodies in immunoblot analysis (compare Figures 4C and 8C), but still
much more potent than the commercial total Rab8 antibody that detects only ∼1000 pg of Rab8A (Figure 8C,
lower panel). MJFF-pRAB8clones-1 to -2 were selected for recombinant protein production as Clone-1 was the
most potent and Clone-2 the most selective.
We next explored whether it was possible to exploit the lack of selectivity of the MJFF-pRAB8 monoclonal
antibodies to immunoprecipitate diverse sets of LRRK2-phosphorylated endogenous Rab proteins.
Immunoprecipitations were undertaken using the MJFF-pRAB8clones-1 and -2 monoclonal antibodies, in parallel
with the polyclonal antibodies, on cell extracts derived from wild-type and LRRK2[R1441C] knock-in MEFs
treated with or without 100 nM MLi-2 prior to cell lysis. The immunoprecipitates were then subjected to
immunoblot analysis with various total Rab protein antibodies. This revealed that MJFF-pRAB8clones-1 and -2
and the polyclonal antibodies immunoprecipitated Rab8A in addition to Rab10 and Rab35 (Figure 9).
Moreover, levels of all of these proteins were higher in LRRK2[R1441C] MEFs compared with wild-type MEFs,
consistent with enhanced phosphorylation of these substrates in the knock-in cells (Figure 9). Furthermore,
treatment with MLi-2 prevented the immunoprecipitation of investigated Rab proteins with the MJFF-pRAB8
antibodies, conﬁrming that their immunoprecipitation with the phospho-Rab8 antibody is dependent on
LRRK2 phosphorylation (Figure 9). Signiﬁcantly increased levels of Rab8A, Rab10 and Rab35 were immuno-
precipitated with the MJFF-pRAB8clones-1 and -2 compared with the polyclonal antibodies (Figure 9), suggesting
that the monoclonal antibodies will be more powerful reagents to immunoprecipitate LRRK2-phosphorylated
Rab proteins than the polyclonal antibodies.
Comparison of conventional immunoblotting and Phos-tag protocols to study
LRRK2-mediated phosphorylation of Rab proteins
Finally, we compared the relative potency of the MJFF-pRAB8 and MJFF-pRAB10 rabbit monoclonal anti-
bodies in a phospho-immunoblot assay with the Phos-tag assay [11]. This was achieved by overexpressing
Rab8A (Figure 10A) or Rab10 (Figure 10B) with LRRK2[Y1699C] in HEK293 cells to induce >50% phosphor-
ylation of these Rab proteins. A serial dilution of these extracts was subjected to electrophoresis on either a
normal polyacrylamide gel (upper panel) or a Phos-tag polyacrylamide gel (lower panel). Both gels were sub-
jected to immunoblot analysis with the same phospho- and total Rab protein antibodies to enable direct
Figure 9. The pan-selective MJFF-pRab8 antibodies immunoprecipiate various LRRK2-phosphorylated Rab proteins.
Littermate wild-type and LRRK2[R1441C] knock-in MEFs were treated ±100 nM MLi-2 for 90 min and lysed. The cell lysates
(5 mg) were subjected to immunoprecipitation using the indicated MJFF-pRab8 monoclonal antibodies (20 mg) or rabbit
polyclonal antibody (E8263) (50 mg). Forty percent of the immunoprecipitates was immunoblotted with total Rab43 antibody,
40% with total Rab35 antibody, 10% with Rab8A antibody and 10% with total Rab10 antibody (all at 1 mg/ml antibody). The
speciﬁcities of the total Rab8A, Rab10 and Rab35 have been previously validated using appropriate A549 CRISPR/CAS9
knock-out cell extracts [12]. Immunoblots were developed with ECL.
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comparison of electrophoresis methods. This revealed that for Rab8A, the conventional immunoblotting assay
was ∼3-fold (total antibody) to 10-fold (phospho-antibody) more sensitive than the Phos-tag method
(Figure 10A). For Rab10, the conventional immunoblotting assay was ∼10-fold (total antibody) to 30-fold
(phospho-antibody) more sensitive than the Phos-tag method (Figure 10A).
Discussion
As a previous work indicated that Rab10 is a key substrate for LRRK2 [10–13], we prioritised generating a
selective antibody recognising endogenous LRRK2-phosphorylated Rab10. This proved more challenging than
anticipated, as polyclonal antibodies were not selective. However, by generating rabbit monoclonal antibodies
and undertaking selectivity screening at each stage of the hybridoma clone selection process, we succeeded in
elaborating antibodies that displayed exquisite selectivity for LRRK2-phosphorylated Rab10 and that were also
very potent. Inspection of the amino acid sequences surrounding the Thr73 LRRK2 phosphorylation site on
Rab10 suggests that the preceding His72 is unique and not found on other Rab proteins containing a Thr
residue phosphorylation site (several Ser-phosphorylated Rab proteins have a preceding His residue) (Figure 1).
We speculate that the unique His-Thr(P) motif in Rab10 accounts for the MJFF-pRab10 antibody selectivity.
The MJFF-pRAB10 monoclonal antibodies readily detect endogenous LRRK2-phosphorylated Rab10 in
immunoblot analysis of 5 mg of MEF extract (express high levels of LRRK2), 20 mg of A549 cell lysate (express
low levels of LRRK2), 30 mg of mouse tissue extract (the lung, spleen and kidney) and 20 mg of the human
brain cingulate cortex (Figures 4–7). The LRRK2-phosphorylated Rab10 is the major band in most of these
immunoblot analyses that are also relatively clean with remarkably little background (Figures 4–7). Using the
MJFF-pRab10 antibodies, we can readily quantify 2–4-fold increases in phosphorylation of Rab10 in MEFs or
tissues derived from LRRK2[G2019S] and LRRK2[R1441G/C] knock-in mice (Figures 4–6). We demonstrate in
an accompanying manuscript that the phospho-speciﬁc MJFF-pRAB10 antibodies can also readily detect
LRRK2-mediated phosphorylation of Rab10 in human-derived neutrophils [23].
The experiments using human brain samples (Figure 7) were designed to evaluate whether the
MJFF-pRAB10 antibodies could be employed to detect Rab10 phosphorylation in human brain for the ﬁrst
Figure 10. Comparison of the phospho-immunoblotting and Phos-tag protocols to study LRRK2-mediated
phosphorylation of Rab proteins.
(A) HEK293 cell extracts overexpressing LRRK2[Y1699C] and the indicated HA-Rab8A (A) or HA-Rab10 (B) were treated
±150 nM MLi-2 for 90 min and then lysed. The indicated amounts of cell lysates were subjected to either conventional
polyacrylamide gel electrophoresis (upper panel) or Phos-tag polyacrylamide gel electrophoresis (lower panel). Proteins on
both gels were transferred to nitrocellulose and subjected to identical immunoblot analysis with indicated antibodies (all at
0.5 mg/ml antibody). The open circles on the Phos-tag gel correspond to the position that phosphorylated Rab protein
migrates, and the closed circle to the position that the dephosphorylated Rab protein migrates. Immunoblots were developed
with ECL.
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time. We used cingulate cortex samples, as this is more readily available than substantia nigra. It has the advan-
tage of providing several milligrams of proteins, which was required to optimise the assay for the detection of
phospho-Rab10 in human brain (Figure 7). Furthermore, even though Parkinson’s disease is mainly charac-
terised by degeneration of dopaminergic neurones in substantia nigra, other regions of the brain, including the
cingulate cortex, are affected by the disease and are therefore interesting to study [31]. In future work, it would
be very interesting to use the MJFF-pRAB10 phospho-speciﬁc antibody to investigate Rab10 phosphorylation
levels in brain samples derived from LRRK2-mutated Parkinson’s disease patients. It will be particularly inter-
esting to perform these experiments in all brain regions available, including substantia nigra and striatum, to
determine how Rab10 phosphorylation levels correlate with the genetic mutations and pathology.
A previous mass spectrometry analysis indicated that Rab8 is also one of the major LRRK2-phosphorylated
Rab proteins in MEFs and mouse brain extract [10,12]. It would therefore be important to develop a selective
antibody that detects LRRK2-phosphorylated Rab8. However, our work indicates that it will be challenging to
obtain a selective phospho-Rab8 antibody, likely due to the high sequence similarity surrounding the LRRK2
phosphorylation site on Rab8 and other Rab proteins (Figure 1). Nevertheless, we believe that the pan-selective
MJFF-pRAB8 antibodies will still have considerable utility due to their ability to immunoprecipitate a subset of
LRRK2-phosphorylated Rab proteins which can then be detected with highly speciﬁc total Rab protein anti-
bodies. Thus far, we have shown that this approach works for detecting LRRK2-phosphorylated Rab8A, Rab10
and Rab35, but it is likely based on immunoblotting data (Figure 8A) that other Rab proteins including Rab3
and Rab43 could be also analysed using this approach. We have recently exploited the less-sensitive
phospho-Rab8 rabbit polyclonal antibodies to immunoprecipitate and analyse LRRK2-phosphorylated Rab pro-
teins by mass spectrometry that revealed Rab3A and Rab43, in addition to many other Rab proteins that are
not phosphorylated by LRRK2 [12].
In future work, it would be interesting to crystallise the MJFF-pRAB8 antibodies with
LRRK2-phosphorylated Rab8A protein or a phospho-peptide antigen encompassing the Thr72 phosphorylation
site to determine whether it would be possible to engineer enhanced speciﬁcity into the MJFF-pRAB8 anti-
bodies. Another possibility would be to immunise rabbits with LRRK2-phosphorylated Rab8A protein rather
than phospho-peptide antigen, which may help with generating selective phospho-speciﬁc Rab8 antibodies or
antibodies that detect a LRRK2 phosphorylation-induced conformation of Rab8A.
Our observations suggest that it may be easier to generate selective antibodies that detect Ser-phosphorylated
Rab proteins such as Rab5 and Rab12, as the polyclonal antibodies raised against these LRRK2-phosphorylated
Rab proteins are more selective than those recognising Thr-phosphorylated Rab proteins (Figure 2). In a previ-
ous work using mass spectrometry, LRRK2-phosphorylated Rab12 was detected in MEFs and mouse brain
[10]. We also detected LRRK2-phosphorylated Rab12 after immunoprecipitation of endogenous Rab12 in
MEFs using sheep polyclonal phospho-speciﬁc Rab12 antibodies (Figure 3C). LRRK2-phosphorylated Rab12
was also observed in human peripheral blood mononuclear cells [13]. We are in the process of generating a
rabbit monoclonal phospho-Rab12 Ser106 antibody that, we anticipate, will complement the selective Rab10
phospho-speciﬁc antibodies to assess LRRK2 in vivo activity. Furthermore, the phospho-Rab12 selective anti-
bodies may be particularly useful for detecting LRRK2 activity in the brain where LRRK2-phosphorylated
Rab10 was not easily detected by either immunoblot analysis (Figure 6D) or by mass spectrometry in a previ-
ous work [10]. In future work, it will be important to investigate in more depth which Rab proteins are the
major LRRK2 substrates in neuronal tissue, a task that will be greatly aided by having access to a wide range of
phospho-speciﬁc antibodies that detect phosphorylated Rab proteins.
Our data also demonstrate that the conventional phospho-immunoblot assay is more sensitive than the
Phos-tag assay in detecting LRRK2-phosphorylated Rab8A and Rab10 (Figure 10). This is partially due to the
lower sensitivity of the total Rab8 and Rab10 antibodies that only detects ∼1000 pg of recombinant protein
compared with 30–10 pg for the phospho-Rab10 antibody (Figures 4C and 8C). Our data are also consistent
with some general loss of both non-phosphorylated and phosphorylated Rab protein associated with the
Phos-tag method (Figure 10). The reasons for this are not clear, but it is possible that the electrophoresis and
subsequent transfer of Rab proteins from a phos-tag gel to nitrocellulose membrane are less efﬁcient than the
conventional polyacrylamide gel and immunoblotting method. Consistent with reduced sensitivity of the
Phos-tag assay, we also found it challenging to detect LRRK2 phosphorylation of Rab10 in human neutrophils
deploying the Phos-tag method [23]. We would therefore recommend that for future work, conventional
phospho-immunoblot assay is deployed as the primary method to evaluate LRRK2-mediated Rab protein phos-
phorylation. However, in order to assess the stoichiometry of Rab protein phosphorylation, for example to
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demonstrate high stoichiometry of Rab10 phosphorylation in a patient sample, as we have done for human
brain cingulate cortex samples (Figure 7B), the Phos-tag assay still has considerable utility.
In summary, we provide a framework of how to develop and characterise phospho-speciﬁc antibodies that
recognise LRRK2-phosphorylated Rab proteins. We describe selective phospho-Rab10 (MJFF-pRAB10) and
pan-selective phospho-Rab8 (MJFF-pRAB8) antibodies that will greatly help the research community in analys-
ing endogenous LRRK2-mediated phosphorylation of Rab proteins. In addition, our initial work suggests that
it should be possible to develop selective antibodies recognising LRRK2-phosphorylated Rab5, Rab12 and
Rab29. We also provide the ﬁrst evidence that the phospho-speciﬁc Rab10 antibody can be employed to detect
elevated phosphorylation of Rab10 in the human brain sample derived from Parkinson’s disease patients. In
future work, it will be important to evaluate whether these antibodies work in additional applications such as
immunohistochemistry, ELISA assay and ﬂuorescence-activated cell sorting. The phospho-speciﬁc antibodies
described in the present study will not only help researchers better analyse LRRK2 biology, but also have the
potential to be deployed as future biomarkers to monitor LRRK2 activity and the impact of inhibitors in future
clinical trials.
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